| Autor: |
Isidoro Pérez Cabeza, Alejandro, González Correa, José Antonio, Chinchurreta Capote, Pedro Antonio, Marques, Rafael Bravo, Mateas, Francisco Ruiz, Cervantes, Gabriel Rosas, Prado, Fidel Mesa, Tejero, Sergio Lopez, Alberca, Almudena Valle, Pérez Cabeza, Alejandro Isidoro, Bravo Marqués, Rafael, Ruiz Mateas, Francisco, Rosas Cervantes, Gabriel, Mesa Prado, Fidel, López Tejero, Sergio, Valle Alberca, Almudena |
| Zdroj: |
Future Cardiology; 2018 Supplement, Vol. 14, p9-16, 8p |
| Abstrakt: |
Aim: To evaluate medication persistence and outcomes in patients with atrial fibrillation after 2 years of treatment with rivaroxaban in routine practice.Methods: Retrospective study of atrial fibrillation patients in whom rivaroxaban was prescribed during the first quarter of 2014 in the healthcare area of Costa del Sol (Málaga).Results: A total of 111 patients (mean age 74.9 ± 10.9 years; 52.3% men; CHA2DS2-VASc 3.6 ± 1.3; HAS-BLED 1.3 ± 0.6) were included. A total of 96.3 and 90.6% of patients remained on rivaroxaban therapy after 1 and 2 years of treatment, respectively. During this period, stroke, net clinical benefit outcome (thromboembolic events, myocardial infarction, cardiovascular death and major bleeding) and cardiovascular death occurred in 3.6, 5.4 and 1.8% of patients, respectively.Conclusion: In routine practice, medication persistence with rivaroxaban was high. Rates of major cardiac events were low. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
